Photodynamic therapy (PDT), a treatment using a lightactivated drug (photosensitiser), is an investigational therapy for several forms of cancer (Marcus and Dugan, 1992) . The photosensitiser, selectively accumulated or retained in neoplastic tissue, produces cytotoxic substances upon activation with light, resulting typically in gross haemorrhagic tissue necrosis.
Intraoperative local treatment of primary or recurrent malignant brain tumours by PDT is currently being investigated, and several phase I/II clinical trials have been reported with evidence of increased survival time (Kostron et al., 1990; Kaye and Hill, 1993) . Depending on the clinical situation, tumour mass, location and previous local treatments, PDT is given with or without prior surgical resection of the tumour and either as a standalone treatment (Muller and Wilson, 1990; Powers et al., 1991) or in combination with radiation or chemotherapy (Kaye, 1989; Noske et al., 1991) . Both intracavitary (Muller and Wilson, 1993) and interstitial techniques Powers et al., 1991) have been used. A critical issue with either technique is the degree of tumour selectivity that can be achieved. The uptake of photosensitiser into tumour may be consistently greater than in normal brain, owing to the intact blood-brain barrier (BBB) of the latter. However, low intrinsic sensitivity of normal brain compared with malignant tissue is also desirable in order to minimise damage to brain adjacent to tumour (BAT), which is within the light treatment field. Haemorrhagic necrosis of malignant and normal brain tissue in patients following PDT has been reported (Muller and Wilson, 1990; Kaye and Hill, 1993) .
In this preclinical study a photodynamic threshold model has been used to describe the dependence of the extent of PDT-induced tissue necrosis on light and photosensitiser doses. The model (Patterson et al., 1990) was derived from the observation of a sharp boundary that usually occurs between PDT-induced tissue necrosis and undamaged adjacent tissue (Berenbaum et al., 1982; Potter, 1989) . The model states that, for a given tissue and photosensitiser combination, necrosis will occur if the number of photons absorbed by the photosensitiser per unit tissue volume exceeds a threshold value (1). Thus, a low intrinsic PDT sensitivity corresponds to a high T-value, and vice versa. The photodynamic threshold is calculated from measured values of the depth (or radius) of coagulative tissue necrosis (re), the light fluence [H(r,) ] at the necrosis boundary, and the photosensitiser concentration in the tissue (C) . The model has been tested in various in vivo animal tumour models and normal tissues (Farrell et al., 1991 (Farrell et al., , 1992a Q Chen, private communication) and has been shown to predict accurately the radius or depth of necrosis.
Only a limited number of quantitative studies describing intracranial tissue response to PDT in preclinical animal models have been published. Evidence to date (Dereski et al., 1991; Chen et al., 1992a,b; Lilge et al., 1993a; Ying et al., 1994) suggests that the photodynamic threshold model holds also for intracranial tissues. Kaye and Morstyn (1987) , using haematoporphyrin derivative (HpD) at 20 mg per kg body weight (bw) and 200 J cm-2 of surface light dose, and Sandeman et al. (1987) , using trisulphonated aluminium chlorophthalocyanine at 0.5 mg per kg bw and 700 J cm-2, observed selective tumour kill in intracranial murine tumour models, while normal brain tissue showed no, or very limited necrosis under these treatment conditions.
Several authors (Cheng et al., 1984; Dereski et al., 1991; Chen et al., 1992a; Leach et al., 1993; Ying et al., 1994) have noted a very high sensitivity of normal brain tissue to PDT using Photofrin as photosensitiser. The first histologically observable changes in normal brain are in structures associated with the BBB, such as endothelial cell damage (Berenbaum et al., 1986) and astrocytic swelling (Yoshida et al., 1992a) . Neuronal injury (Yoshida et al., 1992b) was observed only at longer time delays post PDT. Lindsay et al. (1991) observed photodynamic resistance for intra-cranially grown VMDk tumours in mice, while the same tumour grown subcutaneously appeared sensitive using tetra-m-(hydroxyphenyl) porphyrin (m-THPP) as photosensitiser.
These various data suggest differences in the threshold values of porphyrin-based photosensitisers in the photodynamic response of normal brain tissue, and in particular a higher threshold for HpD compared with Photofrin. [Photofrin (Quadralogic Technologies, Vancouver, BC, Canada) or porfimer sodium, is a commercial version of HpD that is enriched in components believed to have enhanced tumour localisation and high PDT activity.]
The aim of the present study was to determine and compare the PDT thresholds for intracranial PDT of normal brain and an implanted tumour model in the rabbit brain for three porphyrin-based photosensitisers, namely Photofrin, HpD and 56-aminolaevulinic acid (5-ALA), a precursor of the haem synthesis pathway that leads to the in situ production of the photosensitiser protoporphyrin IX (PpIX) (Kennedy and Pottier, 1992 bone, 5 mm posterior to the coronal suture and 5 mm lateral to the sagittal suture. A 25-50 jil cell suspension containing approximately 105 cells was injected through the burr hole into the brain to a depth of 5-6 mm using a 25 G needle (Brem et al., 1990) . After injection the burr hole was closed with bonewax and the scalp incision sutured. After 14 days, before PDT, on inspection of the brain cortex at craniotomy, tumour was sometimes visible at the injection site and in some cases also attached to the dura. This 'leakage' of tumour cells, which occurred mainly in the first few animals in which the injection technique had not been perfected, did not cause any obvious inflammatory response and the bulk of the tumour mass remained well defined. The problem could be eliminated by implantation of the cells in agarose gel as reported by Kaye et al. (1985) . PDT treatment Photofrin was injected i.v., 10 mg per kg bw at 4-6, 24 or 48 h before light activation. For comparison, two animals were injected i.v. with HpD (supplied by Queen Elizabeth Hospital, Woodville, Australia) at 10 mg per kg bw 24 h before light activation, and three animals were injected i.v. with 5-ALA as hydrochloride (98% purity) (Sigma Scientific, St Louis, MO, USA) at 100 mg per kg bw 6 h before light activation. These injected doses are in the range of commonly used doses in preclinical research (Dereski et al., 1991; Chen et al., 1992a; Yoshida et al., 1992a) . For i.v. injection, Photofrin and HpD solutions were made up in 5% dextrose to 10 mg ml-' and 5 mg ml-' respectively. 5-ALA was made up in PBS to 80 mg ml-I and pH balanced to 7.1 with sodium hydroxide (0.1 N).
An air cooled argon -ion laser (Ion Laser Technologies, Salt Lake City, UT, USA) operating in multiline mode (A= 465/488/514 nm) or single-line mode (A= 514 nm) was used as the light source [630 nm is commonly used for these photosensitisers, but a shorter wavelength was chosen in order to confine the treatment to within the tumour volume; previous work has shown that this does not change the measured threshold values (Patterson et al., 1990) ]. The light was coupled via a microscope objective lens into a fused silica optical fibre (numerical aperture 0.25; 320 gm core diameter, 415 gm outer diameter; Polymicro Technologies, Phoenix, AZ, USA). The numerical aperture was slightly overfilled at the input face to obtain a reproducible angular distribution of the light at the cleaved and polished distal end. For introduction into the cranium the fibre was held flush with the end of a 21 G biopsy needle. The delivered power was measured with a thermopile (Scientech, Boulder, CO, USA) immediately before and after irradiation, in all cases varying less than 6% between these two measurements after cleaning the tip. All source and detector fibres were sterilised for 15 min in 0.85% sodium hydroxide solution and rinsed in sterile saline immediately before use.
The light fluence (J cm-2) at the anticipated boundary of necrosis was determined by integrating direct continuous measurements of the local fluence-rate in the target volume during PDT (Powers and Brown, 1986; Lilge and Wilson, 1993) using three implanted optical fibre probes. These fluorescent (rhodamine 640) tipped probes (170 gm outer Intracranial photodynamic therapy L Lilge et al 334 diameter) have been described elsewhere and were calibrated for absolute fluence-rate response (Lilge et al., 1993b (Albritton, 1953) . Surgery for intracranial light irradiation required approximately 1.2-2 h. The skull was exposed and a left parietal craniotomy of 12-15 mm diameter performed. The dura was incised and reflected. The source and detector fibres were positioned under micrometer control to a depth of 6 mm below the cortex surface via biopsy needles. The needles were then retracted, leaving the optical fibres embedded in the white matter, 3 -5 mm from the left hippocampus. In tumour-bearing animals the delivery fibre was placed as close as possible to the initial tumour cell injection site and depth, attempting to target the centre of the tumour. The detector fibres were placed posteriorly or posteromedially to the delivery fibre.
After irradiation the optical fibres were retracted and the scalp was sutured. Recovery from anaesthesia was continuously monitored. Dexamethasone 0.5 mg twice daily and enrofloxacin (Baytril; Haver-Lockhart, Etobicoke, Ontario, Canada) as antibiotic 12.5 mg daily were administered i.m.
The surface of the brain was exposed to a maximum broad-band irradiance of 3.6 J cm-2 (approximately 7 J total energy) from ambient operating room light. At 6 mm depth the contribution of this to the treatment fluence was negligible (< 1%) and could not be detected by the implanted detector probes.
The first five animals in the treatment groups were irradiated with approximately 55 mW delivered power (multiline mode) to minimise the exposure time. However, occasional charring at the delivery fibre tip was observed, and the output was reduced to 42-48 mW (single line) for all subsequent treatments, with no further charring or damage to the fibres. Delivery of 77 -100 J total energy took up to 35 min.
Even although this extreme temperature effect at the fibre tip had been eliminated, there remained the possibility that the PDT treatment light could induce hyperthermia. Normal brain tissue is highly temperature sensitive, and hyperthermia approximately 40 -42°C has been shown to be synergistic with PDT (Dereski et al., 1995a) and can lower PDT threshold values (Farrell et al., 1991) . Hence, in an additional non-tumour-bearing rabbit in situ temperature measurements were made in the brain by inserting three calibrated type-T thermopiles via 25 G needles at 2, 4 and 6 mm from the source fibre at the same depth as the detector fibre array in the treatment groups. All other procedures were as for the PDT treatments, except Figure 1 Experimental set-up for intracranial PDT treatments and light fluence measurements. The delivery and detector fibres were inserted under micrometer control to a depth of 6 mm below the brain surface, into either the white matter or the tumour mass.
was less than I°C at any time or position. Thus, hyperthermia should not have been a significant factor in the tissue response under the irradiation conditions used.
Determination of the radius of PDT-induced tissue necrosis
The animals were sacrificed 24-48 h post PDT treatment (Yoshida et al., 1992b) by i.v. sodium pentobarbital overdose (Euthanyl; Haver-Lockhart, Etobicoke, Ontario, Canada). The brain was immediately removed intact and placed in 10% formalin in PBS. After fixation the brain was sliced into transverse sections 3 mm thick for gross examination. Serial -sections (4 ,um) were cut from those transverse slices that showed the maximum area of necrosis. These were stained with haematoxylin and eosin (H&E) to enhance coagulative necrosis.
The area of induced necrosis, in a 2-D section, was determined by video microscopy at 25 x magnification using a colour CCD camera (Javelin, Japan) and a computer-based image analysis program (Bioquant; R&M Biometrics, Nashville, TN, USA). Necrosis was often delineated by the lateral ventricle or a sulcus, causing non-spherical lesions. The 'effective' radius of necrosis was calculated assuming a spherical lesion with a maximum cross-sectional area equal to the measured area.
In tumour-bearing animals, some necrosis of normal brain from PDT was inevitable, and the area of necrosis comprised both normal and tumour tissue. It has been reported (Dereski et al., 1991; Yoshida et al., 1992b ) that the area of neuronal damage in normal brain usually extends beyond the area of frank coagulative necrosis. This was, therefore, also scored in each animal. The area of frank necrosis corresponds to 'intended' damage in tumour, while neuronal damage is the concomitant extent of damage in adjacent normal brain.
Determination of photosensitiser concentration in tissue
For photosensitiser uptake studies one tumour-bearing animal was sacrificed by i.v. euthanyl overdose at each light treatment time point after photosensitiser injection. The brain was immediately removed and stored at -80°C until further use. The right hemisphere was regarded as normal brain (N) and the mid-section of the left hemisphere as tumour (T). The anterior and posterior parts of the left hemisphere were treated as brain adjacent to tumour (BAT). Aliquots of 100-200 mg of each tissue were weighed and the porphyrins extracted with ether ). The porphyrin concentration was then determined by optical absorption spectroscopy at the Soret band (403 nm), to measure total porphyrin content in the tissue, calibrated by spiking a corresponding control homogenised tissue sample with a known concentration of either Photofrin, HpD or PpIX free acid, each dissolved in a 1:1 mixture of 0.01 N tetrahydrofuran and 0.1 N hydrochloric acid. Since this chemical extraction does not differentiate between exogenous and endogenous porphyrins, the concentration of the latter was measured in tissues from an unsensitised rabbit and subtracted from the uptake in the photosensitiser-injected animals. The use of absorption spectroscopy for photosensitiser quantification rather than fluorescence spectroscopy Intracranial photodynamic therapy L Lilge et al (Vernon et al., 1995) allows the total porphyrin content to be determined, independent of differences in fluorescence yield of the different porphyrin moieties in Photofrin and HpD. It has the disadvantage of lower sensitivity than the fluorimetric technique. The assumption that endogenous porphyrins do not contribute significantly to the photodynamic effect is supported by observations in the light-only control animals (see below).
Determination of the photodynamic threshold value
The photodynamic threshold value, T (photons cm-3), was calculated (Patterson et al., 1990 ) according to T = 2.3ECH (r,) 335 (1) where e is the extinction coefficient (cm-' (jg g-')-') of the photosensitiser at the treatment wavelength, C (,ug g-1) is the tissue concentration of the photosensitiser and H(rc) (photons cm-2) is the photon fluence at the radius of necrosis rc (mm). By defining the photodynamic threshold in units of photons cm-' it becomes independent of the treatment wavelength.
The extinction coefficients of the photosensitisers were measured in dilute solutions (of dextran for Photofrin and HpD, PBS for ALA) in a double-beam spectrophotometer in the green-to-red part of the visible spectrum. The measured values at the treatment wavelength of 514 nm compare well with those in other studies (Profio and Doiron, 1981; Gunter et al., 1989) 
Results
A total of 27 evaluable rabbits received intracranial PDT and local fluence-rate measurements. One animal died of unknown cause within 12 h of PDT treatment. In the three control animals (light -no photosensitiser) only mechanical damage from insertion of the fibre array was observed, with no regional necrosis or zone of neuronal damage seen on histopathology.
As seen in Table II , the tumour-to-normal brain ratio for Photofrin uptake was approximately 12: 1 between 4 and 48 h. Highest porphyrin concentrations were found at short time delays, probably due to circulating drug. The data also suggest that uptake of HpD in normal brain is approximately the same as for Photofrin, consistent with previous findings (Wilson et al., 1988) .
Different parts of the brain are involved in haem synthesis (Verma et al., 1993) , converting 5-ALA to PpIX. Regional differences in synthesis of PpIX from 5-ALA in normal brain have been observed (M Olivo, unpublished results). However, Figure 2 shows examples of the measured fluence rates, ¢D(r), as a function of time during light treatment. The measured fluence rates changed by up to 50% during the course of treatment in individual animals, but no systematic pattern was observed in any of the study groups. As discussed in the appendix, variations in the local fluence rate, as for example in Figure 2c at 300 s, are most likely due to changes in the local optical properties, rather than fluctuations in delivered power, which would cause a corresponding change in all detector readings. Based on the measured fluence rates, @D(r), the total integrated fluence, H(r), at each radial distance, H(r) from the source fibre was calculated and plotted as r H(r) vs r for each animal, as illustrated in Figure 3 . The fluence (J cm-2) at the damage Aw radius could thereby be determined in each animal by linear interpolation of these data, and was typically in the range 10 -14 J cm-2. The fluence rate vs distance measurements also allowed the optical absorption and scattering coefficients of the tissues to be determined, as discussed in the appendix. carcinoma, growing along the major vessels, filling the perivascular space and within the leptomeninges, and with an oedematous BAT region. Figure 4b shows a gross histological section of normal rabbit brain 24 h post PDTtreatment. The PDT-induced lesions in normal brain were characterised by areas of coagulative necrosis with a distinct boundary (Figure 5a ). This area of necrosis was bordered by a rim of vacuoles, interpreted as a border of cerebral oedema. This was followed by a thin rim of non-viable neurons, which appeared shrunken and eosinophilic ( Figure 6 ). The thickness of this rim was generally 200-500 ,m, independent of the photosensitiser type or time delay between its injection and light irradiation. (Figure 7a) , appearing similar to Photofrin-induced coagulative necrosis in the grey matter. No necrosis or subnecrotic effects were found in the white matter.
The measured radii of tissue necrosis, rc, in the different study groups are given in Table III Based on the total fluence at the radius of necrosis, the concentration of the photosensitiser in the tissue and its molar extinction coefficient, the photodynamic threshold value was calculated for each animal according to equation (1). The average values for each study group are listed in Table IV . The photodynamic thresholds for Photofrin-and HpD-treated animals at 24 h were similar.
As a result of the absence of PDT-damage in the white matter of ALA-treated animals, the zone of necrosis was not spherical with the fibre tip at the centre. The upper limit to the threshold value given in Table IV limit was calculated assuming r, = 6 mm, which is the distance from the fibre tip to the dura. Studies to confirm these threshold values are in progress using surface illumination of the grey matter, which will allow accurate determination of the true depth of necrosis. Using neuronal damage rather than necrosis as the biological end point results in lower threshold values:
(1.9+ 1.2, 1.8+0.8 and 1.1 0.5) x 10's photons cm-' at 4-6, 24 and 48 h, respectively, for Photofrin; (2.1 + 1.2) x 1018 photons cm-' at 24 h for HpD.
For simplicity, the effect of photosensitiser photobleaching during light irradiation has not been taken into account in calculating the threshold values above. Extension of equation (1) to include photobleaching has been discussed previously (Wilson, 1992 ). An estimate of the effect can be obtained by considering the fraction of photosensitiser bleached at the radius of necrosis. For example, for Photofrin, the fluence at the radius of necrosis is approximately 10 J cm-2 in both tumour and normal tissue (Figure 3 ), so that, for a photobleaching rate of 0.036 cm2 J-1 (Chapman, 1986; Barclay, 1972) . The choice of the rabbit model restricts the intracranial tumour type that can be used, and there is no glioma model available as there is for the rat (Kaye et al., 1985; Dereski et al., 1995b) . Nevertheless, the uptake ratio of photosensitiser in tumour and BAT vs surrounding normal brain is similar to those reported for some rat glioma models: e.g. the tumour-to-normal ratio of Photofrin concentration at 48 h post injection was approximately 14 in a 9L glioma grown in Fischer rats (Dereski et al., 1995b) , the same as for VX2 in the rabbit brain. The PDT 'curability' of the intracranial VX2 is likely to be different from that of glioma. However, this and the small number of animals used, does not affect the major conclusions of the present study with respect to the PDT threshold and the qualitative comparison between tumour and normal tissue sensitivities. The known immunogenicity of the VX2 tumour in rabbits (Zagzag et al., 1988) should also not alter the threshold values significantly, since the PDT-induced necrosis was measured at a short time interval post treatment.
In these experiments, the doses of photosensitiser used in the PDT-treated animals were high compared with clinical doses, as reviewed by Kostron et al. (1990) , although similar to other preclinical studies (Dereski et al., 1995a,b; Kaye and Morstyn, 1987 al., 1991) , so that the contribution of circulating drug at 48 h can be neglected, and the concentration must be attributed to tissueassociated photosensitiser. Very slow clearance of Photofrin and HpD from normal human brain has also been reported in other studies (Boisvert et al., 1985; Kaye et al., 1985) .
The time course of Photofrin concentration in the tumour was similar to that in normal brain, but with the peak uptake being about 12 times higher, attributable to breakdown of the BBB. Ying et al. (1992) noted in a rat glioma model that the uptake of photosensitiser into malignant tissue increases with progressive degradation of the BBB. As most human brain tumours are currently treated at a late stage, it can be assumed that the BBB is also disrupted, and similarly high uptake can be expected (Origitano et al., 1993) . Some investigators (Pottier and Kennedy, 1990; Woodburn et al., 1992) have pointed out that, in poorly vascularised tumours, including human glioma (Kayama et al., 1991) , the tissue is more acidic, possibly increasing the uptake or retention of photosensitisers such as HpD and Photofrin.
Despite the very low volume uptake of Photofrin and HpD in normal brain, significant necrosis was produced at all times, resulting in a very low photodynamic threshold value compared with other normal tissues (Patterson et al., 1990 ) (see Table V ). The most likely explanation is that the intact BBB results in a very high concentration of photosensitiser in the capillary endothelium, and necrosis results from microvascular damage (Reed et al., 1987) . Our finding of subepithelial accumulations of fibrin and proteinaceous material adjacent to the PDT lesions suggest a subnecrotic effect of PDT on the vasculature.
The decrease of the photosensitiser concentration in normal brain and tumour at longer time intervals is not reflected in a decrease of the radii of necrosis. Thus, the threshold values decrease with time. This can only be explained by either a redistribution of photosensitiser to more sensitive target sites or selective removal of photosensitiser from less sensitive sites. Berenbaum et al. (1986) Intracranial photodynamic therapy The relatively high Photofrin PDT threshold value in the well-vascularised intracranial VX2 tumour is similar to that in the poorly vascularised and poorly differentiated Dunning prostate tumour grown subcutaneously (M Olivo, unpublished results), and may be due to rate-limiting perfusion of oxygen in the intracranial tumour as the result of competitive oxygen use in adjacent brain tissue. This has been suggested by Lindsay et al. (1991) , who observed reduced PDT response of malignant glioma in rats grown intracranially compared with extracranially. Comparative studies of the PDT threshold in the VX2 tumour under these conditions are in progress. Kayama et al. (1991) found that the intratumoral P02 was four times lower than in the brain cortex and up to eight times lower than in arterial blood, measured during surgery in humans. The arterial pao2 measured in our experiments during PDT was close to four times lower than reported in the human study. Hence, very poorly oxygenated regions could be present in the VX2 tumour despite a good vascular supply, resulting in reduced sensitivity to photodynamic therapy (Foster et al., 1991) .
Photofrin PDT vs HpD PDT threshold Kaye and Morstyn (1987) have reported smaller depths of necrosis of normal rat brain vs a glioma tumour model, treated using HpD under similar conditions, suggesting a higher threshold for necrosis in normal brain when using HpD compared with Photofrin. However, we observed no significant differences in the radius of necrosis in normal rabbit brain treated with either HpD or Photofrin. Parallel studies in a 9L glioma rat model (Q Chen and M Dereski, private communication) have found also no difference in the response of normal brain tissue to HpD and Photofrin. In the use of PDT for human patients, there appears to be a greater degree of normal brain response with Photofrin (Muller and Wilson, 1993) than with HpD (Kaye and Hill, 1993) , as observed clinically. With Photofrin, elevated intracranial pressure, approximately double those of a resection-only control group, requiring high doses of steroids, have been reported (Muller and Wilson, 1993) , suggesting significant cerebral oedema. This has not been reported to be a problem with HpD. Conversely, in neither case does there appear to be neurological deficit as result of the treatment, which is consistent with our finding that Photofrin and HpD have similar PDT effects on normal brain. In conclusion, the photodynamic threshold model appears to be applicable to quantify the extent of PDT-induced tissue necrosis in intracranial tissues with the photosensitiser and irradiation parameters used here. The study has confirmed the high intrinsic PDT-sensitivity of normal brain. This is of concern when applying PDT as clinical treatment for human brain tumours. In order to achieve a good therapeutic effect with a wide margin of safety, the tumour-to-normal photodynamic threshold ratio should ideally be much less than unity. Since this is not the case, selective tumour destruction can only be achieved by having a high tumour-to-normal uptake ratio of photosensitiser and by accurate light targeting. Increase in the therapeutic ratio using alternative photosensitisers and/or modulating the PDT effect in normal brain is a worthwhile goal. Assuming that damage to normal brain is caused by vascular stasis, triggered by damage to the endothelium, protection might be achieved by clearance of the photosensitiser from the BBB before light treatment or bleaching of the photosensitiser at the onset of light treatment (Patterson and Wilson, 1994) to prevent endothelial cell damage, or suppression of clotting factor release after the endothelial cell layer is damaged (Ben Hur et al., 1988) , or by administration of thromboxane inhibitors to prevent vascular stasis (Fingar et al., 1993) . Detailed subcellular photosensitiser uptake studies, for example using confocal fluorescence microscopy (M Olivo, unpublished results), can play an important role in evaluating the possible efficacy of some of these interventions.
The observation of neuronal damage beyond the zone of coagulative damage in normal brain with Photofrin or HpD may also reduce the therapeutic efficacy of brain tumour PDT. The extent of neuron damage beyond coagulative Appendix The fluence at the boundary of necrosis can be calculated indirectly by applying a mathematical model of the light distribution in optically turbid media (Driver et al., 1991; Arnfield et al., 1992; Farrell and Patterson, 1992) based on average optical properties of the target tissue. In the present study, in addition to direct determination of the fluence at the radius of necrosis, the local fluence-rate measurements, ¢(r), at the three different radial distances, r, were used to derive the optical interaction coefficients of the target tissues, using a modified solution of the diffusion necrosis becomes smaller for longer time delays between photosensitiser and light administration, favouring longer time delays (Muller and Wilson, 1993) .
For Photofrin the maximum normal-to-tumour threshold ratio was obtained at 24 h. Of the five study groups, 5-ALA had the highest normal-to-tumour threshold ratio in white matter, and could be a very efficient photosensitiser for tumours seeded in this location. However, care will have to be taken to protect haem-synthesising structures in the brain from light irradiation, considering also that photoproducts are created when PpIX is light activated (Charlesworth and Truscott, 1993) and these could have different photoeffectiveness.
The large variation observed during light treatment in the local fluence rate and, hence, in the tissue optical properties emphasises the need for continuous fluence-rate monitoring during clinical PDT. The multifibre detector technique demonstrated might be well suited for deep-seated malignancies when non-invasive monitoring (Farrell et al., 1992b; Farrell and Patterson, 1992) is not applicable.
Finally, the possible relevance of the present work to clinical PDT for treatment of malignant brain tumours should be considered. The low occurrence of reported major neurological deficits with Photofrin or HpD PDT in patients, (Muller and Wilson, 1993; Kaye and Hill, 1993 ) might be interpreted as challenging the present conclusion that normal brain has an intrinsically higher sensitivity to porphyrin-based PDT than brain tumour. However, it should be noted that the fraction of normal brain exposed during PDT in patients has generally been much less than in this rabbit model, even allowing for the fact that the clinical studies have been carried out using 630 nm light, where the penetration in tissue is much greater than at 514 nm. Thus, either there could be damage to normal human brain that is subclinical, or normal human brain does not have high sensitivity compared with brain tumour, or the high sensitivity in the normal rabbit brain is (partially) the result of the large fractional volume exposed or the relatively high photosensitiser doses used. Further studies to examine the last point are in progress. In the absence of evidence to the contrary, it also seems reasonable to proceed with further studies using the present model to examine possible alternative photosensitisers that may have significantly less effect on normal brain tissue and strategies to enhance the PDT sensitivity of intracranial tumour relative to surrounding normal brain. This is likely to be increasingly important as PDT is used to eradicate minimal residual tumour after surgical resection or small tumour foci without prior resection, when tumour selectivity will be critical.
equation (Grosjean, 1956) . This solution of the diffusion equation has been confirmed by Monte Carlo calculations close to the source and is equally accurate for scattering-or absorption-dominated tissues (Arnfield et al., 1992) . The reduced (transport) scattering coefficient, u,', and absorption coefficient, Ma, were derived as free parameters in a gridsearch X-square fit to the measured 4>(r) values and the mean delivered power before and after treatment. A geometrical correction for anisotropic delivery by the cut-end optical fibre was incorporated in the mathematical model Variations in the local fluence-rate, as seen in Figure 2 , are here reflected in these optical properties changing during the course of the treatment, Note that the sudden discontinuity seen in Figure 2 is not reflected in the derived optical properties values. The average values of /la, p,' and p,ff during light treatment are shown in Table Al . The effective attenuation coefficients alternatively derived directly from the semilogarithmic plots of r H(r) vs r, as shown in Figure 3 , are also included in Table Al . The difference between the directly and indirectly determined values was generally less than 15%, in support of the mathematical model used to derive the absorption and scattering coefficients. In some animals the linear regression to calculate jp,,1 directly and the fitting routine to derive JUa and i,' showed significant errors, possibly due to individual detector fibres being close to strongly light-absorbing structures (e.g. blood vessels or blood clot). The precision of these interstitial fluence-rate measurements could be increased either by increasing the number of optical fibre detectors or by a different geometrical arrangement of these around the source fibre.
The average optical properties and penetration depth (1 /y,es) of the 514 nm light in normal brain are similar to published values (Svaasand and Ellingsen, 1983; Chen et al., 1992b) . Literature data for brain tumour are only available for 630 nm light, for which the penetration depth is substantially greater, 2.9 + 1.5 mm (Muller and Wilson, 1986) , than at 514 nm, due mainly to reduced haemoglobin absorption.
Monitoring of the fluence-rate during light treatment was found to be essential, as the fluence-rate distribution in brain tissue could alter unpredictably in the course of treatment, as seen in Figure 2 at particular times and locations. This type of sudden change in fluence rate was seen sporadically in a number of animals during treatment. It is not likely to be a technical artifact, such as movement of the fibre tip or changes in the fibre-detector coupling, since the change was usually transient and reversible. It is also not the result of a sudden loss or gain in delivered light, since this would be seen by all detectors equally. The most probable cause is local tissue disruption in the region of the individual detector fibre tip, such as an altered blood content in a nearby vessel or some bleeding around the detector, although the latter would not be rapidly reversible. The haemoglobin extinction coefficient is very high at 514 nm as used here, so that relatively small changes in local blood content could give marked fluence changes. We have also seen these effects in other tissues, such as the canine prostate (Q Chen, unpublished results).
Considering the slower, systematic trends in optical properties during treatment, reduced optical absorption due to photosensitiser photobleaching can be neglected in normal brain owing to the minimal contribution of the photosensitiser to the overall absorption coefficient (estimated at 0.0038 cm-' vs 0.11 cm-'). However, it has to be considered for Photofrin and HpD in tumour tissue, as up to 15% of the overall absorption can be due to the photosensitiser. Changes in the scattering coefficient could be caused, for example, by oedema or fluid (e.g. cerebrospinal fluid) leaking into the target volume, or by incidental thermal damage to the tissue (King and Rudolf, 1993; Jaywant et al., 1993) , although the latter is unlikely for the temperature changes observed. Direct monitoring of the fluence rate would enable compensation in clinical treatment time for such changes in the tissue optical properties due to the treatment itself.
